Press review 2014

„Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: A fortune-teller’s crystal ball or a viable prognostic tool?“mehr lesen
The Journal of Thoracic and Cardiovascular Surgery, 4. Dezember 2014

„Strategy for prevention of cancers of the esophagus.“mehr lesen
Annals of the New York Academy of Sciences (New York), Oktober 2014

„The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes.“mehr lesen
The Journal of Thoracic and Cardiovascular Surgery, 3. September 2014

“Das Prädiktor-Gen – ein Paradigmenwechsel”mehr lesen
Ärzte exklusiv, Aug.–Sept. 2014

Diagnose per Molekül – mehr lesen
ChemieReport.at, Mai 2014